PRISM 3
 

About the Study

 
Draft1_Stocksy_txp71234e98Bt7200_Large_786573.jpg

ABOUT THE STUDY

Senior Fighting Recurrent C. Diff Infections.jpg

We know that enrolling in a clinical study is an important and personal choice, and we're committed to making participation as easy as possible. 

Our priority is supporting patients and their caregivers as they seek a solution to recurrent C. difficile.


  • No colonoscopy, no enema, no bowel prep. The study treatment is a pill – not another invasive procedure.

  • Dedicated medical care. Participants will have regular visits with clinical staff and can receive the results at the end of the study.

  • Free transportation and coverage of study-related costs. We’re committed to ensuring that all participants can easily access study-related care.

  • All participants may be eligible to receive the study drug.  Any patient who experiences a recurrence during the study will have the opportunity to qualify for the investigational treatment.

  • Help solve recurrent C. difficileBe part of the community working toward a long-term solution.


What to Expect?

Before joining the PRISM 3 study, you will be screened to find out if you are eligible. If you are eligible and choose to enroll you will:

  • Meet with your participating doctor to be randomly assigned to receive either a single dose of the study drug or a placebo (no active ingredients)

  • Have 5 visits with dedicated and experienced clinical staff over the next six months, who will evaluate your health and progress

  • Collect stool samples throughout the study (using the provided, at-home collection kits)

All study-related expenses, including transportation, medical testing, and clinical care, will be provided at no cost.

What if I experience a recurrence (relapse)?

Whether you are given the study drug or a placebo, you may be eligible to receive the capsule with active ingredients if you experience an episode of C. difficile infection within 8 weeks of starting the study. This will be part of an “open label extension study” – a way to make sure that patients who experience recurrences have the opportunity to receive the investigational medication.


We know that enrolling in a clinical study is an important and personal choice, and we're committed to making participation as easy as possible. 

Our priority is supporting patients and their caregivers as they seek a solution to recurrent C. diff.


  • No colonoscopy, no enema, no bowel prep. The study treatment is a pill – not another invasive procedure.

  • Dedicated medical care. Participants will have regular visits with clinical staff and can receive the results at the end of the study.

  • Free transportation and coverage of study-related costs. We’re committed to ensuring that all participants can easily access study-related care.

  • All participants may be eligible to receive the study drug.  Any patient who experiences a recurrence during the study will have the opportunity to qualify for the investigational treatment.

  • Help solve recurrent C. diffBe part of the community working toward a long-term solution.


What to Expect?

Before joining the PRISM 3 study, you will be screened to find out if you are eligible. If you are eligible and choose to enroll you will:

  • Meet with your participating doctor to be randomly assigned to receive either a single dose of the study drug or a placebo (no active ingredients)

  • Have 5 visits with dedicated and experienced clinical staff over the next six months, who will evaluate your health and progress

  • Collect stool samples throughout the study (using the provided, at-home collection kits)

All study-related expenses, including transportation, medical testing, and clinical care, will be provided at no cost.

What if I experience a recurrence (relapse)?

Whether you are given the study drug or a placebo, you may be eligible to receive the capsule with active ingredients if you experience an episode of C. diff infection within 8 weeks of starting the study. This will be part of an “open label extension study” – a way to make sure that patients who experience recurrences have the opportunity to receive the investigational medication.